Booz Allen Hamilton (BAH) Q2 2027 Earnings Call Transcript

Booz Allen reported Q2 FY2027 adjusted diluted EPS of $1.76, up 18.1% year over year, and raised its FY2027 EPS guidance to $6.50–$6.70 from $6.00–$6.35. Revenue fell 3.9% to $2.8 billion, with national security revenue up 1% (6% excluding billable expenses) and civil revenue down 15%; total backlog rose 2% to $41 billion. The company completed its $729 million Ultra I&C Mission Solutions acquisition and cited strong demand for defense technology and cyber products, while noting federal funding uncertainty and continued civil-business pressure.

Analysis

The key underwriting shift is from labor-volume growth toward monetizing reusable technology and taking more fixed-price/outcome-based risk. If execution holds, revenue per employee and profit growth could outpace headcount—but the same shift raises downside convexity: delivery overruns now sit more directly with BAH, so rising fixed-price mix is not automatically margin accretive. Watch contract-level execution, not just mix.

Near term, national-security funded work gives the company a better demand buffer than civil, but pipeline is not bookings: continuing-resolution delays can push awards and collections even when mission demand is intact. Civil’s sequential stabilization is the near-term proof point. The EPS raise is less clean than it appears as a recurring run rate: tax benefits, reduced share count and a divestiture earn-out contribute, while management expects second-half margin seasonality and investment spending. Elevated DSO, acquisition costs and 3.3x net leverage make cash conversion and integration more important than headline EPS.

The contrarian risk is that investors capitalize cyber/defense-tech aspirations like scaled product economics before private-beta products convert to repeatable revenue. Ultra’s stated margin profile is management’s claim; verify contribution, organic growth and integration costs in filings and subsequent results. Over 6–18 months, successful productization and fixed-price execution could support higher-quality growth; delayed federal awards or cost overruns would expose the labor-centric base and constrain deleveraging.

Key Decisions for Investors

• Own BAH only as a measured, multi-quarter transformation position; avoid adding on EPS strength alone. Consider a starter position after the immediate earnings reaction, with adds contingent on the next report confirming national-security growth and civil revenue stabilizing sequentially.
• Treat the next 1–3 months as a conversion test: monitor funded backlog, award timing, DSO and free-cash-flow delivery against guidance. A continuing-resolution extension or further civil award slippage weakens the near-term setup even if the qualified pipeline remains strong.
• Keep the structural thesis conditional: track fixed-price contract execution and evidence that cyber/defense-tech products are generating repeatable revenue, not just customer interest or lab results. Failure to expand margins as mix shifts—or a material increase in delivery costs—would falsify the operating-leverage thesis.
• Risk controls: reassess if civil fails to stabilize sequentially, national-security funded backlog reverses, or cash conversion deteriorates enough to impede deleveraging. The upside is gradual margin and growth quality improvement; the downside is multiple compression if product economics remain unproven while acquisition-related leverage and working capital absorb cash.